Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01388075

Enrollment

150

Registered

2011-07-06

Start date

2011-07-31

Completion date

Unknown

Last updated

2011-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Keywords

induction, CYP2C9, Genetic variability, Expression

Brief summary

The genetic factors associated with variability in CYP2C9 induction have not been elucidated. The hypothesis underlying this study is that following 7 days treatment with rifampicin, a known CYP450 inducer, the genetic variability in regulatory elements controlling CYP2C9 expression will be associated with the magnitude of change in INR response to warfarin and in CYP2C9-mediated warfarin metabolism.

Interventions

DRUGRifampicin

oral, 450 mg/day , 7 days

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy subjects

Exclusion criteria

* Consumption of any medication during 30 days * Smoking * Alcohol consumption

Design outcomes

Primary

Measure	Time frame
International Normalized Ratio (INR)	6 weeks

Secondary

Measure	Time frame
Warfarin concentration	6 weeks

Countries

Israel

Contacts

Primary ContactMordechai Muszkat, MD

muszkatm@hadassah.org.il972-6777111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026